TY - JOUR
T1 - Transcatheter aortic valve implantation
T2 - First greek experience
AU - Spargias, Konstantinos
AU - Manginas, Athanassios
AU - Pavlides, Gregory
AU - Khoury, Mazen
AU - Stavridis, George
AU - Rellia, Panagiota
AU - Smirli, Anna
AU - Thanopoulos, Apostolos
AU - Balanika, Marina
AU - Polymeros, Spyros
AU - Thomopoulou, Sofia
AU - Athanassopoulos, George
AU - Karatasakis, George
AU - Mastorakou, Renata
AU - Lacoumenta, Stavroula
AU - Michalis, Alkis
AU - Alivizatos, Petros
AU - Cokkinos, Dennis
PY - 2008/11
Y1 - 2008/11
N2 - Introduction: Percutaneous aortic valve replacement represents an alternative to conventional open-heart surgery for selected high-risk patients without the need for sternotomy, aortotomy, or cardiopulmonary by-pass. We present the first Greek series of transcatheter prosthetic aortic valve implantation procedures, performed in our centre. Methods: All 12 patients (age 81 ± 5 years) had severe, symptomatic, calcific aortic stenosis and were judged not to have a reasonable surgical option by a medical team including experienced cardiac surgeons. The patients' mean logistic EuroSCORE was 34 ± 15% (min 11%, max 61%). Eight (8) of them underwent transfemoral (SAPIEN, Edwards 23 mm valve in 7 and 26 mm in 1 patient) and 4 transapical (26 mm in 2 and 23 mm in 2 patients) prosthetic aortic valve implantation, all in the cardiac catheterisation laboratory under general anaesthesia. Results: The procedural, in-hospital and 2-month (mean follow up 50 days, min 17, max 122 days) mortality was 0%. The length of hospital stay was 8 ± 2 days (min 5, max 12 days). The aortic valve area increased from 0.64 ± 0.14 cm 2 to 1.83 ± 0.14 cm2 and the mean pressure gradient decreased from 57 ± 23 mmHg to 10 ± 3 mmHg post-implantation (p<0.001 for both). The patients' mean NYHA functional status improved from 2.8 ± 0.7 to 1.3 ± 0.5 at follow-up (p<0.001). Conclusions: Our initial experience with transcatheter prosthetic aortic valve implantation demonstrates that it can be performed safely and with excellent short and mid-term clinical outcomes.
AB - Introduction: Percutaneous aortic valve replacement represents an alternative to conventional open-heart surgery for selected high-risk patients without the need for sternotomy, aortotomy, or cardiopulmonary by-pass. We present the first Greek series of transcatheter prosthetic aortic valve implantation procedures, performed in our centre. Methods: All 12 patients (age 81 ± 5 years) had severe, symptomatic, calcific aortic stenosis and were judged not to have a reasonable surgical option by a medical team including experienced cardiac surgeons. The patients' mean logistic EuroSCORE was 34 ± 15% (min 11%, max 61%). Eight (8) of them underwent transfemoral (SAPIEN, Edwards 23 mm valve in 7 and 26 mm in 1 patient) and 4 transapical (26 mm in 2 and 23 mm in 2 patients) prosthetic aortic valve implantation, all in the cardiac catheterisation laboratory under general anaesthesia. Results: The procedural, in-hospital and 2-month (mean follow up 50 days, min 17, max 122 days) mortality was 0%. The length of hospital stay was 8 ± 2 days (min 5, max 12 days). The aortic valve area increased from 0.64 ± 0.14 cm 2 to 1.83 ± 0.14 cm2 and the mean pressure gradient decreased from 57 ± 23 mmHg to 10 ± 3 mmHg post-implantation (p<0.001 for both). The patients' mean NYHA functional status improved from 2.8 ± 0.7 to 1.3 ± 0.5 at follow-up (p<0.001). Conclusions: Our initial experience with transcatheter prosthetic aortic valve implantation demonstrates that it can be performed safely and with excellent short and mid-term clinical outcomes.
KW - Aortic valve stenosis
KW - Percutaneous valve repair
KW - Prosthetic aortic valve
KW - SAPIEN
UR - http://www.scopus.com/inward/record.url?scp=57149110674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57149110674&partnerID=8YFLogxK
M3 - Article
C2 - 19110926
AN - SCOPUS:57149110674
SN - 1011-7970
VL - 49
SP - 397
EP - 407
JO - Hellenic Journal of Cardiology
JF - Hellenic Journal of Cardiology
IS - 6
ER -